Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
EU — Italia · scadenza 21/09/2027
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Scadenza: 21/09/2027
Fonte: eu_funding_tenders
Tipo: EU
Pagina ufficiale: Apri la scheda sulla fonte ufficiale
Scheda (fonte ufficiale)
Topic metadata
- EU Programme: Horizon Europe (ID 43108390)
- Call identifier: HORIZON-MISS-2027-02
- Call name: Supporting the implementation of the Cancer Mission
- Type: Topic
- Opening date: 10/02/2027
- Next deadline: 21/09/2027
- Keywords: HORIZON-MISS-2027-02-CANCER-03, HORIZON-MISS-2027-02, Anticancer therapy, Biophotonics, Imaging, image and data processing, Cancer and its biological basis, Quality-of-life, Radiation therapy, Surgery
Topic description
Expected Outcome:
Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
- Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided
Iscriviti o accedi per leggere e ricevere aggiornamenti sui finanziamenti.
Iscriviti oraHai già un account? Accedi